An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC

Who May Qualify: - Voluntary agreement to provide written willing to sign a consent form. - Man or woman ≥ 18 years and ≤75 years of age at the time of enrollment. - Histologically and/or cytologically-confirmed locally advanced or metastatic NSCLC. - Measurable lesion according to RECIST 1.1. - Progression after systemic treatment for advanced NSCLC. - Available archived paraffin-embedded or fresh tumor tissue from the primary tumor or metastasis for submission to the central laboratory. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Measurable and/or non-measurable disease as per RECIST 1.1 criteria. - your organs (liver, kidneys, etc.) are working well enough based on blood tests as assessed by laboratory tests. - Male or female subjects of child-producing potential must agree to use avoidance of pregnancy measures during the study and for 6 months after the last day of treatment. Who Should NOT Join This Trial: - Patient has received previous treatment with DR5 targeted regimen or antibody-MMAE conjugate. - Brain metastases unless asymptomatic, stable and not requiring steroids for at least 7 days prior to start of study treatment. - Subject with positive HCV-Ab, Anti-HIV or positive HBS-Ag with copies of HBV DNA \> ULN. - Pregnancy, lactation, or breastfeeding. Always talk to your doctor about whether this trial is right for you.